Novel SEDDS Formulation

Type: Cancer Drug

Location: Australia, US

With excellent pre-clinical results following testing for toxicity, resistance, neurotoxicity, blood brain barrier penetration and the potential for broad efficacy across 30+ cancers, the drug has great potential to replace the Taxol chemotherapy family and possibly many other approved chemotherapy treatments in both US, European and Low and Middle income country healthcare systems.